Biotech layoffs are easing, but is the worst over?

FierceBiotechAnalysts cut enGene cancer sales forecast after updated data widen gap to J&J

BioPharma DiveFDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended

10x Genomics News10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up - Zacks Investment Research

Eli LillyWill Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. - The Motley Fool

AbbottAbbott's Medical Device Strategy Supports Long-Term Growth Outlook - The Globe and Mail

FDA News ReleasesFDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics

BioPharma DiveLilly, Gilead lead pharma’s M&A boom

Endpoints News'Pharma, not really’: Top young AI talent shuns careers at big drugmakers

Bio-RadBio-Rad to Participate in Upcoming Investor Conferences - Business Wire

PharmaVoiceBiotech layoffs are easing, but is the worst over?

Thermo FisherThermo Fisher’s New Cell Therapy Bioreactor And Bioprocess Hub Might Change The Case For Investing In TMO - simplywall.st

Eli LillyLilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site - BioSpace